

Oral Immunotherapy for Food Allergy References

- Buchanan, A. D., Green, T. D., Jones, S. M., Scurlock, A. M., Christie, L., Althage, K. A., ... Buks, A. W. (2007). Egg oral immunotherapy in non-anaphylactic children with egg allergy. *J Allergy Clin Immunol*, 19(1), 199-205. <https://doi.org/10.1016/j.jaci.2006.09.016>
- Chinthrajah, R. S., Cao, S., Dunham, T., Sampath, V., Chandra, S., Chen, M., Sindher, S., Nadeau, K. (2020). Oral Immunotherapy for peanut allergy: The pro argument. *WAO Journal*, 13(8). <https://doi.org/10.1016/j.waojou.2020.100455>
- Chu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., ... Schünemann, H. J. (2019). Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *The Lancet*, 393 (10187), p2222-2232. [www.thelancet.com/journals/lancet/article/PIIS0140-6736\(19\)30420-9/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30420-9/fulltext)
- de Silva et al. (2022). Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. *Allergy (GA²LEN publication)*: <https://onlinelibrary.wiley.com/doi/10.1111/all.15211>
- DunnGalvin, A., McMahon, S., Ponsonby, A. L., Hsia, K. C., & Tang, M. L. K. (2017). The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. *Allergy*, 73(3), 560-568. <https://doi.org/10.1111/all.13330>
- Epstein-Rigbi, N., Goldberg, M. R., Levy, M.B., Nachshon, L., & Elizur, A., (2019). Quality of Life of Food-Allergic Patients Before, During, and After Oral Immunotherapy. *J Allergy Clin Immunol in Practice*. 7(2), 429-436. <https://doi.org/10.1016/j.jaip.2018.06.016>
- Fiocchi, A., Artesani, M.C., Fierro, V., Riccardi, C., Dahdah, L., Mennini, M. (2020). Oral Immunotherapy for peanut allergy: The Con argument. *WAO Journal*, 13(8). <https://doi.org/10.1016/j.waojou.2020.100445>
- Grzeskowiak, L. E., Tao, B., Knight, E., Cohen-Woods, S., & Chataway, T. (2020). Adverse events associated with peanut oral immunotherapy in children – a systematic review and meta-analysis. *Scientific Reports*, 10, 659. <https://doi.org/10.1038/s41598-019-56961-3>
- Jones et al. (2022). Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. *The Lancet* (21) 02390-4. <https://doi.org/10.1016/S0140-6736>

Nurmatov, U., Dhimi, S., Arasi, S., Pajno, G. B., Fernandez-Rivas, M., Muraro, A., ... Sheikh, A. (2017). Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. *Allergy*, 72(8). <https://doi.org/10.1111/all.13124>

Shaker et al. (2021). The cost-effectiveness of preschool peanut oral immunotherapy in the real-world setting. *J Allergy Clin Immunol Pract*. <https://doi.org/10.1016/j.jaip.2021.02.058>

Tang, M. L. K., Ponsonby, A-L., Francesca Orsini, F., Dean Tey, D, Marnie Robinson M., Su, E. L., ... Donath, S. (2015). Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol*, 135(3), 737-744. <https://doi.org/10.1016/j.jaci.2014.11.034>